Multiple sclerosis: Could Roche’s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?
Posted:
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of primary progressive multiple sclerosis (PPMS) after allegations that the drug was approved despite internal concerns about its efficacy in women and a potential increased risk of breast cancer.
Microsoft announced a strategic partnership with Mayo Clinic to develop and deploy a frontier AI model specifically for healthcare, combining Mayo Clinic's clinical expertise with the tech giant's technologies.
Read more here.
Healthcare is evolving faster than ever — driven by digital transformation, AI, new care models, and increasing pressure on health systems to deliver better outcomes with fewer resources.
But innovation only works when the right people come together in the…
Attendees
Sponsors and Exhibitors
Contact us